New COVID-19 vaccine shows promise in small trial
NCT ID NCT05279456
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a new COVID-19 vaccine called SpikoGen in 39 adults who had never received a COVID-19 vaccine. Participants received two doses one month apart, followed by a third booster dose either one or three months later. The goal was to see how well the vaccine triggered an immune response and whether it was safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SpikoGen vaccine (recombinant spike protein with Advax-CpG55.2 adjuvant)
What this could lead to
If successful, this could provide a safe and effective COVID-19 vaccine option for people who have not yet been vaccinated.
What could go wrong
This is a small, early-phase trial with only 39 participants, so results may not apply to the general population. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ARASMI
Adelaide, South Australia, 5042, Australia